MentionFox
Home › IPO pipeline › iSpecimen Inc.
IPO filings · Form S-1, F-1, 424B4, RW

iSpecimen Inc. IPO

Before you invest in iSpecimen Inc.

MentionFox check on iSpecimen Inc.: no red flags found in 17 sources (checked 6 November 2026). mentionfox.com/c/ipo/ispecimen

Check iSpecimen Inc. before you invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about iSpecimen Inc.?

iSpecimen Inc.'s initial public offering: every registration filing, amendment, final prospectus and withdrawal, with the facts quoted from the filings and each one linked.

iSpecimen Inc. priced its initial public offering at $1.30 a share, to list on the Nasdaq under the symbol ISPC. It filed a Form S-1 registration statement for an initial public offering on October 18, 2024. As of November 6, 2026, its final prospectus is on file (Form 424B4, August 7, 2026).

3 more IPO filings on the Nasdaq, Q3 2026 ↓

Sell to companies like iSpecimen Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · What it is: Final prospectus filed: the offering is priced · 424B4
  • · What it is: Registration statement amended · S-1/A
  • · What it is: Registration statement amended · S-1/A
  • · What it is: Registration statement filed · S-1
  • · What it is: Registration statement amended · S-1/A
StatusPriced
TickerISPC
ExchangeNasdaq
Offering price$1.30
First filed2024-10-18
Filings17

iSpecimen Inc. filed a Form S-1 registration statement for an initial public offering on 2024-10-18. It has amended it 10 times. It filed its final prospectus on 2026-08-07, at a public offering price of $1.30 per share. Each fact below is quoted from the filing named with it.

Also on the record for iSpecimen Inc.

DateRecordFigureOur pageSource
August 31, 2026Leadership change: Shahin Behroyan appointed, Chief Executive Officer—Leadership changesSource

Check before you invest in iSpecimen Inc.: the warning signs and who's behind it, free.

Free to see. No signup.

Keep reading

More on iSpecimen Inc. and the records around it.

iSpecimen Inc. elsewhere on the record

Also filing to list on the Nasdaq

IPO filings on the Nasdaq in Q3 2026, newest first.

Want the whole picture on iSpecimen Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on iSpecimen Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on iSpecimen Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    18 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

What the filings say

Listing

Our common stock is listed on Nasdaq under the symbol “ISPC”.From the 424B4 filed 2026-08-07

Shares offered

We are offering on a best-efforts basis 996,231 shares of our common stock, par value $0.0001 per share (the “Shares”) at a public offering price of $1.30 per share.From the 424B4 filed 2026-08-07

Offering price

We are offering on a best-efforts basis 996,231 shares of our common stock, par value $0.0001 per share (the “Shares”) at a public offering price of $1.30 per share.From the 424B4 filed 2026-08-07

Underwriters

WestPark Capital, Inc. (“WestPark”) is acting as representative of the underwriters (the “Representative”).From the 424B4 filed 2025-07-25

Use of proceeds

We intend to use the net proceeds from the private placement for working capital purposes, including up to $900,000 in marketing expenses.From the 424B4 filed 2026-08-07

Revenue

Revenue decreased by approximately $2,151,000, or 75%, from approximately $2,864,000 for the three months ended June 30, 2024 to approximately $713,000 for the three months ended June 30, 2025.From the S-1/A filed 2025-10-06

Net loss or income

For the years ended December 31, 2025 and 2024, we reported net losses of $10,487,532 and $12,497,805, respectively.From the S-1/A filed 2026-07-17

Timeline

FiledWhat it isFiling
2024-10-18Registration statement filedS-1
2024-10-31Final prospectus filed: the offering is priced424B4
2025-05-02Registration statement filedS-1
2025-05-23Registration statement amendedS-1/A
2025-06-11Registration statement amendedS-1/A
2025-06-27Registration statement amendedS-1/A
2025-07-08Registration statement amendedS-1/A
2025-07-25Final prospectus filed: the offering is priced424B4
2025-08-20Registration statement filedS-1
2025-08-25Registration statement amendedS-1/A
2025-09-08Registration statement amendedS-1/A
2025-10-06Registration statement amendedS-1/A
2025-12-19Registration statement amendedS-1/A
2026-06-24Registration statement filedS-1
2026-07-06Registration statement amendedS-1/A
2026-07-17Registration statement amendedS-1/A
2026-08-07Final prospectus filed: the offering is priced424B4

Tools for this story

Each opens in a new tab, filled in for iSpecimen Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.

Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/ipo/ispecimen
Last updated 2026-11-06
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
iSpecimen Inc. IPO (ISPC, Nasdaq): priced at $1.30 a share. MentionFox, 2026-11-06. https://mentionfox.com/ipo/ispecimen